한글목차

Lorecivint(SM04690)는 Wnt 경로의 저분자 억제제이며, 관절 내 주사제로 투여되는 골관절염 질환 개량신약(DMOAD)으로 개발 중입니다. 매질대조 전임상 데이터에 따르면, 로레시비빈트는 연골 생성, 연골 파괴 지연, 염증 억제라는 관절 건강에 대한 세 가지 효과를 가진 이중 작용기전을 가지고 있는 것으로 나타났습니다. 핵 내 키나아제인 CLK2와 DYRK1A를 억제하여 Wnt 경로, 연골세포, 염증에 작용하는 LOR의 이중 작용기전은 연골세포의 분화와 기능 증가를 통해 OA를 개선하고 항염증 작용을 통해 증상을 개선할 수 있습니다.

주요 6개국, 캐나다 및 한국에서 SM04690 시장에 대해 조사했으며, 시장의 개요와 2024-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 골관절염에 대한 SM04690의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 SM04690 시장 평가

• 골관절염에 대한 SM04690의 시장 전망
• 주요 6개국, 캐나다 및 한국의 분석
  • 주요 6개국, 캐나다 및 한국에서 골관절염에 대한 SM04690의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국
  • 캐나다
  • 한국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"SM04690 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SM04690 for osteoarthritis in the six major markets. A detailed picture of the SM04690 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SM04690 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SM04690 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

Lorecivivint (SM04690) is a small-molecule inhibitor of the Wnt pathway administered as an intra-articular injection and is developing as a potential disease-modifying drug for osteoarthritis (DMOAD). Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three effects on joint health: generation of cartilage, slowing of cartilage breakdown, and reduction of inflammation. Inhibition of nuclear kinases CLK2 and DYRK1A leads to effects on the Wnt pathway, chondrocytes, and inflammation. This dual mechanism of LOR potentially modifies OA through increased chondrocyte differentiation and function and benefits symptoms through anti-inflammatory activity.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SM04690 description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on SM04690 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SM04690 research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around SM04690.
• The report contains forecasted sales of SM04690 for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for SM04690 in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SM04690 Analytical Perspective by DelveInsight

• In-depth SM04690 Market Assessment

This report provides a detailed market assessment of SM04690 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

• SM04690 Clinical Assessment

The report provides the clinical trials information of SM04690 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SM04690 dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to SM04690 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SM04690 in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of SM04690 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SM04690 in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of SM04690?
• What is the clinical trial status of the study related to SM04690 in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SM04690 development?
• What are the key designations that have been granted to SM04690 for osteoarthritis?
• What is the forecasted market scenario of SM04690 for osteoarthritis?
• What are the forecasted sales of SM04690 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to SM04690 for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. SM04690 Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SM04690 Market Assessment

• 5.1. Market Outlook of SM04690 in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of SM04690 in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SM04690 in the United States for Osteoarthritis
  • 5.3.2. Market Size of SM04690 in Germany for Osteoarthritis
  • 5.3.3. Market Size of SM04690 in France for Osteoarthritis
  • 5.3.4. Market Size of SM04690 in Italy for Osteoarthritis
  • 5.3.5. Market Size of SM04690 in Spain for Osteoarthritis
  • 5.3.6. Market Size of SM04690 in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of SM04690 in Canada for Osteoarthritis
  • 5.3.8. Market Size of SM04690 in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options